James Lang Biography and Net Worth

Director of OptimizeRx

Mr. Lang brings to OptimizeRx more than 25 years of experience in healthcare data, analytic, and technology enabled business services.

Lang presently serves as an executive advisor to Water Street, a strategic private equity firm focused exclusively on building market-leading companies in healthcare. He is also a director of BioVie, a development-stage company pioneering an innovative therapeutic that targets complications due to liver cirrhosis.

Previously, Mr. Lang served as CEO of Decision Resources Group, DRG, a leading healthcare research and consulting company providing high-value healthcare industry analysis and insights, where he helped transform the company into an industry leader. Earlier, he was president of Strategic Decisions Group, a premier global strategy consultancy, and he expanded the life sciences practice and later sold it to IMS Health.

He is an active private investor and advisor with healthcare companies, including Boston Heart Diagnostics (acquired by Eurofins) and AlphalmpactRx (acquired by IMS Health).

James Lang holds a BS summa cum laude in electrical and computer engineering from the University of New Hampshire, and earned an MBA with distinction from the Tuck School of Business where he was named an Edward Tuck Scholar.

He currently guest lectures at the Tuck School of Business in strategy and decision-making.

What is James Paul Lang's net worth?: The estimated net worth of James Paul Lang is at least $5.71 million as of March 14th, 2025. Mr. Lang owns 389,452 shares of OptimizeRx stock worth more than $5,705,472 as of December 5th. This net worth approximation does not reflect any other investments that Mr. Lang may own. Learn More about James Paul Lang's net worth.
How do I contact James Paul Lang?: The corporate mailing address for Mr. Lang and other OptimizeRx executives is 400 WATER STREET SUITE 200, ROCHESTER MI, 48307. OptimizeRx can also be reached via phone at (248) 651-6568 and via email at [email protected]. Learn More on James Paul Lang's contact information.
Has James Paul Lang been buying or selling shares of OptimizeRx?: James Paul Lang has not been actively trading shares of OptimizeRx during the past quarter. Most recently, on Friday, March 14th, James Paul Lang bought 321,408 shares of OptimizeRx stock. The stock was acquired at an average cost of $7.60 per share, with a total value of $2,442,700.80. Following the completion of the transaction, the director now directly owns 389,452 shares of the company's stock, valued at $2,959,835.20. Learn More on James Paul Lang's trading history.
Who are OptimizeRx's active insiders?: OptimizeRx's insider roster includes Douglas Baker (CFO), William Febbo (CEO), James Lang (Director), Marion Odence-Ford (General Counsel), Miriam Paramore (Insider), Stephen Silvestro (Insider), and Patrick Spangler (Director). Learn More on OptimizeRx's active insiders.
Are insiders buying or selling shares of OptimizeRx?: During the last twelve months, OptimizeRx insiders bought shares 2 times. They purchased a total of 341,408 shares worth more than $2,542,900.80. During the last twelve months, insiders at the sold shares 2 times. They sold a total of 12,740 shares worth more than $224,863.80. The most recent insider tranaction occured on October, 3rd when CEO Stephen L Silvestro sold 1,620 shares worth more than $30,375.00. Insiders at OptimizeRx own 5.6% of the company. Learn More about insider trades at OptimizeRx.
Information on this page was last updated on 10/3/2025.

James Paul Lang Insider Trading History at OptimizeRx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/14/2025	Buy	321,408	$7.60	$2,442,700.80	389,452
8/19/2022	Buy	6,000	$16.45	$98,700.00	38,660

James Paul Lang Buying and Selling Activity at OptimizeRx

OptimizeRx Company Overview

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.

Today's Range

Now: $14.65

$14.12

$14.75

50 Day Range

MA: $17.67

$13.58

$21.68

2 Week Range

Now: $14.65

$3.99

$22.25

Volume

143,518 shs

Average Volume

286,132 shs

Market Capitalization

$273.08 million

P/E Ratio

35.80

Dividend Yield

N/A

Beta

1.1